UrgoTouch® is a laser technology that:
- Decreases the scar volume by up to 53%. *
- Can be used on all skin phototypes (I to VI)
- Requires 1 single session in the operating room at the end of any body surgery.
UrgoTouch® is currently present in the French and Spanish markets where more than 30,000 patients have benefited from our treatment thanks to over 300 surgeons who trust our medical device.
UrgoTouch® optimizes the scarring process
The scarring process takes place in 4 main phases in which growth factors notably instruct other cells to start the collagen production.
To obtain an aesthetic and elastic scar, there must be a balance between the synthesis of:
- Type I collagen: thicker, more rigid
- Type III collagen: thinner, more flexible, essential to scar aesthetics and elasticity
If Type 1 collagen production overpowers Type III Collagene, the process will result in a more fibrotic and less elastic scar, raising the odds of creating an unaesthetic scar.
This process is unpredictable UrgoTouch® optimizes the scar by reducing the randomness in the healing process associated with this molecular pathway.
It induces a 50°C temperature on the suture to safely activate Heat shock protein HSP70. Experimental studies demonstrated that HSP70 could play a role in the modulation of the inflammatory response, thus reducing the production of type I collagen as well as inflammatory molecules, leading to improved healing results for patients. **
Backed by strong clinical studies
The SLASH study was conducted on 40 patients undergoing breast reduction surgery. Each patient had only 1 scar out of 2 treated with UrgoTouch®.
The scars were then analyzed by:
– a 3D photo software
– 2 medical investigators (after 14 days, 6 weeks, 3 months, 6 months and 1 year)
– Patients themselves
Patients and investigators were unaware of which scar had been treated UrgoTouch®.
Results:
- Up to 53% of volume reduction in breast reduction scars*, analyzed by the software.
- Twice as many patients preferring their laser-treated scar as the number of patients preferring their control scar (p = 0.024).
- 100% of the UrgoTouch® scars were judged better by investigators.
*A 1 Year Follow-up of Post-operative Scars After the Use of a 1210nm Laser Assisted Skin Healing (LASH) Technology: A Randomized Controlled Trial. D.Casanova, ed. Aesthetic Plastic Surgery Journal. Feb 2017 – *Réduction de 53 % observée chez un patient présentant un phototype foncé – La moitié des 80 cicatrices ont été traitées avec UrgoTouch
**Mordon S, Capon A, et al. Lasers thermiques et cicatrisation cutanée. Med Sci (Paris). 2010 Jan
